Projected Annual Lecanemab Treatment Eligibility in an Irish Regional Specialist Memory Clinic.

Publisher: John Wiley Country of Publication: England NLM ID: 8710629 Publication Model: Print Cited Medium: Internet ISSN: 1099-1166 (Electronic) Linking ISSN: 08856230 NLM ISO Abbreviation: Int J Geriatr Psychiatry Subsets: MEDLINE

Publication: Chichester : John Wiley
Original Publication: Chichester, Sussex, England ; [New York] : Wiley, c1986-

Alzheimer Disease*/diagnosis ; Eligibility Determination*; Humans ; Female ; Male ; Aged ; Retrospective Studies ; Ireland ; Aged, 80 and over ; Middle Aged ; Patient Selection ; Biomarkers/cerebrospinal fluid ; Biomarkers/analysis

Objectives: The advent of Disease Modifying Therapies (DMTs) for the treatment of Alzheimer's Disease (AD) has the potential to transform the lives of those with early AD. Timely identification of eligible patients is needed to ensure treatments are delivered during a narrow window of therapeutic opportunity. Appropriate clinical service design will hinge on improved understanding of future demands, thus there is a pressing need to investigate patient eligibility in real world clinical cohorts. The primary aim of this study is to assess the eligibility by appropriate use criteria (AUC) for lecanemab therapy in a real-world, undifferentiated clinical patient cohort attending a Regional Specialist Memory Clinic (RSMC), with the secondary aims of determining the proportion of patients with biomarker positive Alzheimer's Disease (AD) who would be eligible for lecanemab therapy by AUC. Clinical trial eligibility criteria were also applied to both groups and discrepancies that exist between eligibility rates explored.
Methods: A retrospective cohort study of all new patients attending a RSMC from 1st January 2022 to 31st December 2022 was conducted. Data collected included demographic details, outcomes of diagnostic assessments and comorbidities. MRI images, where indicated, were reviewed. Amyloid positivity was defined as either Amyloid and Tau positive (A+T+) or Amyloid positive with a positive P-Tau/Ab42 ratio on cerebrospinal fluid (CSF) testing. Appropriate use criteria (AUC) and clinical trial criteria for lecanemab were applied. Proportion of eligible patients was calculated.
Results: Eleven (5.9%) of 188 new patient attenders were eligible (average age 66.7 years [SD 8.9], 63.6% female) by AUC, with 26.2% of patients with biomarker positive Alzheimer's Disease eligible for lecanemab therapy. The most common reason for exclusion was a lack of biomarker confirmation of AD pathology followed by cognitive ineligibility (based on defined cognitive testing cut-offs) at the time of referral and/or initial assessment. Only 40.4% of patients had CSF testing for AD biomarkers while almost 20% of the patients with biomarker positive AD were excluded due to lack of a screening MRI in the previous 12 months.
Conclusion: In this study, the potential eligibility rate by AUC of the entire patient cohort (5.9%) was limited by the small proportion of patients who had CSF testing for AD biomarkers. So while disease-modification with Lecanemab is a welcome therapeutic advance, although only a small proportion of people currently attending specialist services will be eligible. Successful delivery of DMTs will require significant resource allocation and optimisation of referral pathways to facilitate early identification of potentially eligible patients.
(© 2024 The Author(s). International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.)

G. M. McKhann, D. S. Knopman, H. Chertkow, et al., “The Diagnosis of Dementia Due To Alzheimer's Disease: Recommendations From the National Institute on Aging‐Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Alzheimer’s & Dementia 7, no. 3 (2011): 263–269, https://doi.org/10.1016/j.jalz.2011.03.005.
GBD 2019 Dementia Forecasting Collaborators, “Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019,” Lancet Public Health 7, no. 2 (2022): e105–e125, https://doi.org/10.1016/s2468‐2667(21)00249‐8.
“2023 Alzheimer's Disease Facts and Figures,” Alzheimer's and Dementia 19, no. 4 (2023): 1598–1695.
A. Serrano‐Pozo, M. P. Frosch, E. Masliah, and B. T. Hyman, “Neuropathological Alterations in Alzheimer Disease,” Cold Spring Harbor Perspectives in Medicine 1, no. 1 (2011): a006189, https://doi.org/10.1101/cshperspect.a006189.
C. R. Jack Jr., D. A. Bennett, K. Blennow, et al., “NIA‐AA Research Framework: Toward a Biological Definition of Alzheimer's Disease,” Alzheimer’s & Dementia 14, no. 4 (2018): 535–562, https://doi.org/10.1016/j.jalz.2018.02.018.
B. Dubois, H. Hampel, H. H. Feldman, et al., “Preclinical Alzheimer's Disease: Definition, Natural History, and Diagnostic Criteria,” Alzheimer’s & Dementia 12, no. 3 (2016): 292–323, https://doi.org/10.1016/j.jalz.2016.02.002.
J. H. Lee, S. K. Jeong, B. C. Kim, K. W. Park, and A. Dash, “Donepezil Across the Spectrum of Alzheimer's Disease: Dose Optimization and Clinical Relevance,” Acta Neurologica Scandinavica 131, no. 5 (2015): 259–267, https://doi.org/10.1111/ane.12386.
J. S. Birks and R. J. Harvey, “Donepezil for Dementia Due To Alzheimer's Disease,” Cochrane Database of Systematic Reviews 6, no. 6 (2018): Cd001190, https://doi.org/10.1002/14651858.cd001190.pub3.
J. R. Sims, J. A. Zimmer, C. D. Evans, et al., “Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER‐ALZ 2 Randomized Clinical Trial,” JAMA 330, no. 6 (2023): 512–527, https://doi.org/10.1001/jama.2023.13239.
C. H. van Dyck, C. J. Swanson, P. Aisen, et al., “Lecanemab in Early Alzheimer’s Disease,” New England Journal of Medicine 388, no. 1 (2023): 9–21, https://doi.org/10.1056/nejmoa2212948.
S. Budd Haeberlein, P. Aisen, F. Barkhof, et al., “Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease,” Journal of Prevention of Alzheimer's Disease 9, no. 2 (2022): 197–210, https://doi.org/10.14283/jpad.2022.30.
R. C. Petersen, P. S. Aisen, J. S. Andrews, et al., “Expectations and Clinical Meaningfulness of Randomized Controlled Trials,” Alzheimer’s & Dementia 19, no. 6 (2023): 2730–2736, https://doi.org/10.1002/alz.12959.
H. Dolphin, A. H. Dyer, L. Morrison, S. D. Shenkin, T. Welsh, and S. P. Kennelly, “New Horizons in the Diagnosis and Management of Alzheimer’s Disease in Older Adults,” Age and Ageing 53, no. 2 (2024): afae005, https://doi.org/10.1093/ageing/afae005.
A. H. Dyer, H. Dolphin, S. D. Shenkin, et al., “Emerging Disease Modifying Therapies for Older Adults With Alzheimer Disease: Perspectives From the EuGMS Special Interest Group in Dementia,” European Geriatric Medicine 14, no. 5 (2023): 919–923, https://doi.org/10.1007/s41999‐023‐00846‐2.
L. Jönsson, A. Wimo, R. Handels, et al., “The Affordability of Lecanemab, an Amyloid‐Targeting Therapy for Alzheimer's Disease: An EADC‐EC Viewpoint,” Lancet Regional Health–Europe 29 (2023): 100657, https://doi.org/10.1016/j.lanepe.2023.100657.
M. S. Albert, S. T. DeKosky, D. Dickson, et al., “The Diagnosis of Mild Cognitive Impairment Due To Alzheimer's Disease: Recommendations From the National Institute on Aging‐Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease,” Alzheimer’s & Dementia 7, no. 3 (2011): 270–279, https://doi.org/10.1016/j.jalz.2011.03.008.
F. H. Bouwman, G. B. Frisoni, S. C. Johnson, et al., “Clinical Application of CSF Biomarkers for Alzheimer's Disease: From Rationale to Ratios,” Alzheimer's and Dementia: Diagnosis, Assessment & Disease Monitoring 14, no. 1 (2022): e12314, https://doi.org/10.1002/dad2.12314.
O. Hansson, S. Lehmann, M. Otto, H. Zetterberg, and P. Lewczuk, “Advantages and Disadvantages of the Use of the CSF Amyloid β (Aβ) 42/40 Ratio in the Diagnosis of Alzheimer's Disease,” Alzheimer's Research & Therapy 11, no. 1 (2019): 34, https://doi.org/10.1186/s13195‐019‐0485‐0.
J. Cummings, L. Apostolova, G. Rabinovici, et al., “Lecanemab: Appropriate Use Recommendations,” Journal of Prevention of Alzheimer's Disease 10, no. 3 (2023): 362–377, https://doi.org/10.14283/jpad.2023.30.
M. F. Folstein, S. E. Folstein, and P. R. McHugh, “‘Mini‐mental State’. A Practical Method for Grading the Cognitive State of Patients for the Clinician,” Journal of Psychiatric Research 12, no. 3 (1975): 189–198, https://doi.org/10.1016/0022‐3956(75)90026‐6.
J. Hobson, “The Montreal Cognitive Assessment (MoCA),” Occupational Medicine 65, no. 9 (2015): 764–765, https://doi.org/10.1093/occmed/kqv078.
J. R. Hodges and A. J. Larner, “Addenbrooke’s Cognitive Examinations: ACE, ACE‐R, ACE‐III, ACEapp, and M‐ACE,” in Cognitive Screening Instruments (Cham, Springer, 2016), 109–137, https://doi.org/10.1007/978‐3‐319‐44775‐9.
Z. Togher, H. Dolphin, C. Russell, M. Ryan, S. P. Kennelly, and S. O'Dowd, “Potential Eligibility for Aducanumab Therapy in an Irish Specialist Cognitive Service‐Utilising Cerebrospinal Fluid Biomarkers and Appropriate Use Criteria,” International Journal of Geriatric Psychiatry 37, no. 8 (2022): 1–5, https://doi.org/10.1002/gps.5789.
J. Cummings, G. Rabinovici, A. Atri, et al., “Aducanumab: Appropriate Use Recommendations Update,” Journal of Prevention of Alzheimer's Disease 9, no. 2 (2022): 221–230, https://doi.org/10.14283/jpad.2022.34.
I. G. McKeith, T. J. Ferman, A. J. Thomas, et al., “Research Criteria for the Diagnosis of Prodromal Dementia With Lewy Bodies,” Neurology 94, no. 17 (2020): 743–755, https://doi.org/10.1212/wnl.0000000000009323.
A. Padovani, S. Caratozzolo, L. Rozzini, A. Pilotto, A. Benussi, and G. Tedeschi, “‘Real‐World’ Eligibility for Aducanumab Depends on Clinical Setting and Patients' Journey,” Journal of the American Geriatrics Society 70, no. 2 (2022): 626–628, https://doi.org/10.1111/jgs.17530.
M. Canevelli, P. D. Rossi, P. Astrone, E. Consorti, N. Vanacore, and M. Cesari, “‘Real World’ Eligibility for Aducanumab,” Journal of the American Geriatrics Society 69, no. 10 (2021): 2995–2998, https://doi.org/10.1111/jgs.17390.
R. R. Pittock, J. A. Aakre, A. M. Castillo, et al., “Eligibility for Anti‐Amyloid Treatment in a Population‐Based Study of Cognitive Aging,” Neurology 101, no. 19 (2023): e1837–e1849, https://doi.org/10.1212/wnl.0000000000207770.
A. A. S. Laurell, A. V. Venkataraman, T. Schmidt, et al., “Estimating Demand for Potential Disease‐Modifying Therapies for Alzheimer's Disease in the UK,” British Journal of Psychiatry 224, no. 6 (2024): 198–204, https://doi.org/10.1192/bjp.2023.166.
E. Connolly, A. O'Connor, A. Fallon, S. O'Dowd, and S. P. Kennelly, “Reader Response: Eligibility for Anti‐Amyloid Treatment in a Population‐Based Study of Cognitive Aging,” Neurology 103, no. 3 (2024): e209343, https://doi.org/10.1212/wnl.0000000000209343.
J. C. Arbanas, C. L. Damberg, M. Leng, et al., “Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program,” JAMA Internal Medicine 183, no. 8 (2023): 885–889, https://doi.org/10.1001/jamainternmed.2023.1749.
The National Dementia Office, H.S.E, The National Dementia Office Clinician Survey: Dementia Diagnostic Processes and Practices in Ireland (Tullamore, Ireland: Health Service Executive Location, 2019), 18.
E. Begley, M. Gibb, G. Kelly, F. Keogh, and S. Timmons, Model of Care for Dementia in Ireland (Tullamore, Ireland: HSE, 2023), 52.
L. Cook, H. Souris, and J. Isaacs, The 2019 National Memory Service Audit (London: Dementia Clinical Network, NHS England, 2020), 8, https://www.england.nhs.uk/london/wp-content/uploads/sites/8/2020/04/The-2019-national-memory-service-audit.pdf.
C. G. Withington and R. S. Turner, “Amyloid‐Related Imaging Abnormalities With Anti‐Amyloid Antibodies for the Treatment of Dementia Due To Alzheimer's Disease,” Frontiers in Neurology 13 (2022): 862369, https://doi.org/10.3389/fneur.2022.862369.

R118-2020 Meath Foundation, Tallaght University Hospital; 203930/B/16/Z Wellcome Trust and the Health Research Board; Health Service Executive, National Doctors Training and Planning and the Health and Social Care, Research and Development Division

Keywords: Alzheimer's disease; disease modifying therapy; eligibility; lecanemab

0 (Biomarkers)

Date Created: 20241009 Date Completed: 20241009 Latest Revision: 20241009

20241010

10.1002/gps.6157

39384333